IPG-CANDESARTAN TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CANDESARTAN CILEXETIL

Disponible depuis:

MARCAN PHARMACEUTICALS INC

Code ATC:

C09CA06

DCI (Dénomination commune internationale):

CANDESARTAN

Dosage:

32MG

forme pharmaceutique:

TABLET

Composition:

CANDESARTAN CILEXETIL 32MG

Mode d'administration:

ORAL

Unités en paquet:

30/1000

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Descriptif du produit:

Active ingredient group (AIG) number: 0135220004; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2016-08-19

Résumé des caractéristiques du produit

1
PRODUCT MONOGRAPH
PR
IPG-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Date of Preparation:
August 19, 2016
Marcan Pharmaceuticals Inc.
77 Auriga Drive, Suite #4
Ottawa, Ontario
K2E 7Z7
CONTROL# 196962
2
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................................
3
SUMMARY PRODUCT INFORMATION
........................................................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................................................
3
CONTRAINDICATIONS
.................................................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................................
8
DRUG INTERACTIONS
...............................................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................................................
17
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................................................
20
STORAGE AND
STABILITY..........................................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................................
23
PART II: SCIENTIFIC INFORMATION
.....................